MDGL logo

MDGL Madrigal Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$379.10
-17.64 (-4.45%)

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) cl…

Market Cap: $8.81Bwww.madrigalpharma.com

Price

No data yet.

Social Signal Score

41
5d
27
2 mentions
—
30d
45
21 mentions
—
60d
44
21 mentions
—
90d
47
24 mentions
—
rss: 6 · news: 18

Analyst Ratings

25 analysts
Buyconsensus
Strong Buy 0Buy 22Hold 2Sell 1Strong Sell 0
Avg price target$669.22+76.5%
Low $533Median $670High $962
Current Consensus

Revenue

$431.27M
$0.00$143.76M$287.51M$431.27M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-11.04
$-12.55–$-8.83
7 analysts
FY2026
$-2.02
$-3.72–$-0.19
8 analysts
FY2027
$7.00
$0.07–$14.53
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
William J. Sibold
Sector
Healthcare
Industry
Biotechnology
Employees
915
Beta
-1.00
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
5.90
www.madrigalpharma.com